Publications by authors named "Aina Liz Alves Cesar"
Background: We aimed to evaluate the costs of GenoType® MTBDRplus and MTBDRsl incurred during the diagnosis of first- and second-line drug-resistant tuberculosis (TB) in São Paulo, Brazil.
Methods: Mean and activity-based costs of GenoType® were calculated in a referral laboratory for TB in Brazil.
Results: The mean cost value and activity-based cost of GenoType® MTBDRplus were USD 19.
Article Synopsis
- * Mycobacterium kansasii was the most common NTM identified, present in about 11.5% of analyzed patients.
- * Of the patients who met the diagnostic criteria, nearly half received treatment, with a high cure rate of about 75.8% among those treated, with dyspnea and cough being the most common symptoms.
Purpose: The present study aimed at testing a new formulation of mesalazine linked to chondroitin sulfate and its components alone in the treatment of actinic proctitis in rats.
Methods: Forty-seven female Wistar rats were submitted to pelvic radiation and divided into eight groups: control A, mesalazine A, chondroitin A, and conjugate A, gavage of the according substance two weeks after irradiation and sacrifice three weeks after oral treatment; control C, mesalazine C, chondroitin C, and conjugate C, sacrifice six weeks after oral treatment. The rectum was submitted to histological characterization for each of the findings: inflammatory infiltrate, epithelial degeneration, mucosal necrosis, and fibrosis.
Even when treated adequately, pulmonary tuberculosis can lead to pulmonary sequelae. Patients treated for PTB between 2012 and 2016 answered a standardized questionnaire and underwent chest radiography and spirometry, measurement of absolute pulmonary volume, Diffusing Capacity for Carbon Monoxide (DLCO) and the 6-min walk test (6MWT) on two occasions: within the first year after the end of treatment (follow-up 1), and one and two years after follow-up 1 (follow-up 2). A total of 55 patients they underwent spirometry, 23 (41.
View Article and Find Full Text PDF